Domestic demand lifts Torrent and Mankind in June quarter
India-focused growth powered June-quarter results: Torrent Pharma’s domestic business rose 19% while Mankind Pharma’s India formulations grew 11%, outperforming pressure in US generics markets.
What happened
Torrent Pharmaceuticals · Torrent Pharma and Mankind posted strong June-quarter earnings, supported by double-digit growth in India-focused businesses.
Key facts
- Torrent revenue from operations: ₹4,921 crore, up 55% YoY
- Torrent net profit: ₹566 crore, up 3% YoY
- Torrent base business: ₹3,720 crore, up 17% YoY
- Torrent domestic business growth: 19%
- Mankind revenue: ₹4,031 crore, up 12.9% YoY
- Mankind net profit: ₹574 crore, up 29.1% YoY
- Mankind India formulations growth: 11%
- Domestic pharmaceutical market growth: 12% in April-May
Why this matters
The results increase the strategic value of India formulations assets, distribution reach and brands that can strengthen domestic scale while reducing reliance on US generics.
What to watch
- India pharmaceutical market growth versus Torrent's 19% domestic growth and Mankind's 11% formulations growth.
- Prescription volumes and market-share movement in chronic therapies, especially cardiology, diabetes and CNS.
- US generic price erosion, new competitor entries, product approvals and launch timing.
- Domestic sales-force additions, marketing-spend intensity and resulting EBITDA-margin movement.
- Any revision to full-year India-growth or consolidated-margin guidance.
- Increase promotional intensity in high-growth chronic, cardiometabolic and specialty segments.
- Prioritize domestic brand launches, doctor coverage expansion and selective acquisitions over low-return US generic opportunities.
- Use domestic operating leverage to fund differentiated US launches and compliance investments rather than broad US price competition.
- Highlight India revenue mix, prescription growth and domestic margin trends in guidance to reinforce the earnings narrative.